Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double Blind, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of IBI306 in Healthy Subjects

Next Previous
X
Search
Trial Profile

A Randomized, Double Blind, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of IBI306 in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tafolecimab (Primary) ; Tafolecimab (Primary)
  • Indications Hypercholesterolaemia
  • Focus Adverse reactions
  • Sponsors Innovent Biologics

    • Most Recent Events

    • 01 Sep 2020 Results assessing safety and efficacy from two studies: phase 1 single ascending does study (n=58) and phase 2 multiple ascending dose study presented at the ESC Congress 2020 - Annual Congress of the European Society of Cardiology
    • 30 Aug 2020 According to an Innovent Biologics media release, Professor Yimin Cui, director of the clinical trial center and the director the Institute of Pharmacology in Peking University First Hospital is also the leading PI of this study (CIBI306A101).
    • 30 Aug 2020 According to an Innovent Biologics media release, this study results were successfully presented in the 2020 European Society of Cardiology (ESC) annual conference (August 29 to September 1, Central European Summer Time) as e-Poster.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top